On Februrary 18, 2010, Commissioner Thomas Rosch delivered a speech to the In-House Counsel Forum on Pharmaceutical Antitrust. His speech mostly skipped over topics which he has addressed previously – pay-for-delay, authorized generics, and follow-on biologics, and instead mostly focused on some of the relatively new topics in pharmaceuticals and antitrust, including FDA citizen petitions, product hopping, refusals to license IP, and bundled pricing. Rosch’s speech does not reveal any shift in the FTC’s position regarding these issue areas, but it reinforced the attention that pharmaceutical companies will receive from the FTC under the current leadership.